This session will focus on HHS and FDA's recent efforts to rein in misleading drug advertising and promotion. We will discuss the implications of FDA's recent activities, including: 

• key takeaways from FDA’s warning and untitled letters;
• DTC TV ads;
• a planned proposal to close the “adequate provision loophole”; and
• social media and influencer marketing.

Join us for an informative presentation and discussion as we navigate the sudden changes in drug advertising and promotion. 

For questions or for information about registration, contact Sydney Forte.